Industry Partner Update: PepGen
Defeat Duchenne Canada is committed to bringing the latest in Duchenne muscular dystrophy research and drug development to you – our Canadian Duchenne community.
Join Jane Larkindale, Vice President of Clinical Science at PepGen, as she discusses the latest information about PGN-EDO51, the company’s lead product candidate for the treatment of people living with Duchenne muscular dystrophy whose mutations are amenable to exon 51 skipping, as well as details on their upcoming studies, including CONNECT1 in Canada.
Click the button to the left to read their latest press release and register for this webinar below.
PepGen’s Enhanced Delivery Oligonucleotide (EDO) technology is engineered to optimize the delivery of therapeutic oligonucleotides, including exon-skipping oligonucleotides, which is a major challenge that limits their efficacy. PGN-EDO51 is being evaluated for the treatment of Duchenne muscular dystrophy (DMD), which is amenable to exon 51 skipping. In 2023, PepGen is planning to initiate two clinical trials to assess the safety and efficacy of repeat doses of PGN-EDO51 in boys and young men living with DMD.
Learn more about PGN-EDO51 and earlier-stage candidates for other exons during this webinar.